Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
125.59
+1.89 (+1.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
May 15, 2025
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above...
Via
StockStory
Topics
World Trade
Exposures
Tariff
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
May 14, 2025
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Cash-Producing Stocks Skating on Thin Ice
May 13, 2025
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
Earnings Scheduled For May 1, 2025
May 01, 2025
Via
Benzinga
14 Analysts Have This To Say About Biogen
April 22, 2025
Via
Benzinga
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
May 12, 2025
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...
Via
StockStory
Topics
Government
Stocks
World Trade
Exposures
Political
Tariff
US Equities
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
May 06, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...
Via
StockStory
4 Stocks to Buy for a Potential “Summer Panic”
May 04, 2025
Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create...
Via
InvestorPlace
Exposures
COVID-19
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
May 01, 2025
Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.
Via
Benzinga
Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
May 01, 2025
Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
May 01, 2025
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Biogen Earnings: What To Look For From BIIB
April 30, 2025
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
World Trade
Exposures
Artificial Intelligence
Tariff
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
April 24, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via
StockStory
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
April 16, 2025
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...
Via
Benzinga
Topics
Government
Exposures
Political
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
April 16, 2025
Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.
Via
Benzinga
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
April 15, 2025
From
Biogen Inc.
Via
GlobeNewswire
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
April 10, 2025
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.
Via
Investor's Business Daily
Topics
Government
Exposures
Political
Product Safety
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
April 07, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
April 04, 2025
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Via
Benzinga
Topics
Government
World Trade
Exposures
Political
Tariff
What 14 Analyst Ratings Have To Say About Biogen
April 04, 2025
Via
Benzinga
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
April 02, 2025
From
Biogen Inc.
Via
GlobeNewswire
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
March 28, 2025
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.
Via
Benzinga
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
March 27, 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.
Via
The Motley Fool
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
March 24, 2025
From
Biogen Inc.
Via
GlobeNewswire
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
March 24, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
March 21, 2025
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Via
Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
March 20, 2025
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
March 19, 2025
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.
Via
Benzinga
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
March 11, 2025
From
Biogen Inc.
Via
GlobeNewswire
Indexes Swimming In Red Ink On Recession Fears
March 10, 2025
Stocks are looking to extend last week's losses, as recession fears grip Wall Street.
Via
Talk Markets
Topics
Economy
Stocks / Equities
Exposures
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.